Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Pharma
Novartis touts trial win, nabs priority review for Fabhalta
Fabhalta led to a statistically significant 38.3% reduction of proteinuria (protein in the urine) in patients with IgA nephropathy, Novartis said.
Eric Sagonowsky
Apr 15, 2024 4:22pm
BMS touts KRAS confirmatory trial win after Amgen's stumble
Mar 29, 2024 10:35am
BMS' Zeposia comes up short in Crohn's disease study
Mar 29, 2024 8:15am
Exelixis reveals Cabometyx data that led to early trial end
Oct 22, 2023 3:30am
Roche's subcutaneous Ocrevus stacks up to original IV version
Oct 11, 2023 7:22am
Apellis hits setback in a trial of pegcetacoplan in ALS
Apr 24, 2023 11:29am